Geropharm, the biotechnology company, has recently unveiled a novel medication containing atomoxetine. This drug aims to cure attention deficit hyperactivity disorder in both children (aged six and above) and adults.
More than 300 meta-analyses and randomized clinical trials have been carried out on Atomoxetine, making it the most extensively researched molecule for the treatment of ADHD in the Russian Federation.
Atomoxetine has the highest level of evidence in the treatment of ADHD. The company reports that “Cogniter” improves attention and normalizes behavior, affects the key link in ADHD, optimizing the balance of neurotransmitters.
